JP2017165748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017165748A5 JP2017165748A5 JP2017083327A JP2017083327A JP2017165748A5 JP 2017165748 A5 JP2017165748 A5 JP 2017165748A5 JP 2017083327 A JP2017083327 A JP 2017083327A JP 2017083327 A JP2017083327 A JP 2017083327A JP 2017165748 A5 JP2017165748 A5 JP 2017165748A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- group
- solution
- acid
- trimethylcyclohex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 17
- 239000002105 nanoparticle Substances 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000004676 glycans Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 239000012062 aqueous buffer Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000011026 diafiltration Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- -1 cationic lipid Chemical class 0.000 claims 12
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 claims 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 8
- 229960001727 tretinoin Drugs 0.000 claims 8
- 150000004492 retinoid derivatives Chemical class 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 4
- LMMRBBYYUIBMHI-UHFFFAOYSA-N 9-(2,6,6-trimethylcyclohexen-1-yl)nonanoic acid Chemical compound CC1=C(CCCCCCCCC(O)=O)C(C)(C)CCC1 LMMRBBYYUIBMHI-UHFFFAOYSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims 4
- 229960002916 adapalene Drugs 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 4
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 4
- 229930002330 retinoic acid Natural products 0.000 claims 4
- 229960003471 retinol Drugs 0.000 claims 4
- 235000020944 retinol Nutrition 0.000 claims 4
- 239000011607 retinol Substances 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- UPHFJVMAJPDXRB-UHFFFAOYSA-N 3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nonanoic acid Chemical compound OC(=O)CC(C)CCCC(C)CCC1=C(C)CCCC1(C)C UPHFJVMAJPDXRB-UHFFFAOYSA-N 0.000 claims 3
- VQBJUJRROIKNNI-UHFFFAOYSA-N n-[3-[2-[2-(3-aminopropoxy)ethoxy]ethoxy]propyl]-3-[2-[2-[2-[2-[3-[3-[2-[2-(3-aminopropoxy)ethoxy]ethoxy]propylamino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide Chemical compound NCCCOCCOCCOCCCNC(=O)CCOCCOCCOCCOCCOCCC(=O)NCCCOCCOCCOCCCN VQBJUJRROIKNNI-UHFFFAOYSA-N 0.000 claims 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 2
- IXPNELVVWRMWJI-UHFFFAOYSA-N 2,6-diamino-n-[3-[2-[2-[3-[3-[2-[2-[2-[2-[3-[3-[2-[2-[3-(2,6-diaminohexanoylamino)propoxy]ethoxy]ethoxy]propylamino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]propoxy]ethoxy]ethoxy]propyl]hexanamide Chemical compound NCCCCC(N)C(=O)NCCCOCCOCCOCCCNC(=O)CCOCCOCCOCCOCCOCCC(=O)NCCCOCCOCCOCCCNC(=O)C(N)CCCCN IXPNELVVWRMWJI-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 229920001202 Inulin Polymers 0.000 claims 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- SBCVJZHHHVYKNM-UHFFFAOYSA-M [2-[bis(2-tetradecanoyloxyethyl)amino]-2-oxoethyl]-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCC(=O)OCCN(C(=O)C[N+](C)(C)CCO)CCOC(=O)CCCCCCCCCCCCC SBCVJZHHHVYKNM-UHFFFAOYSA-M 0.000 claims 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 229960000304 folic acid Drugs 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 2
- 229940029339 inulin Drugs 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- FFIDVTCKFVYQCZ-UHFFFAOYSA-N 1,3,3-trimethylcyclohexene Chemical compound CC1=CC(C)(C)CCC1 FFIDVTCKFVYQCZ-UHFFFAOYSA-N 0.000 claims 1
- UDCIXXPNPRLQKM-UHFFFAOYSA-N 2-cyclohexylnonanoic acid Chemical compound CCCCCCCC(C(O)=O)C1CCCCC1 UDCIXXPNPRLQKM-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229930182558 Sterol Chemical class 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229920000447 polyanionic polymer Polymers 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- OKPQBUWBBBNTOV-UHFFFAOYSA-N Kojibiose Natural products COC1OC(O)C(OC2OC(OC)C(O)C(O)C2O)C(O)C1O OKPQBUWBBBNTOV-UHFFFAOYSA-N 0.000 description 1
- NBGXQZRRLOGAJF-UHFFFAOYSA-N Maltulose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)(CO)OCC1O NBGXQZRRLOGAJF-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-XIOYNQKVSA-N Melibiulose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-XIOYNQKVSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- OVVGHDNPYGTYIT-VHBGUFLRSA-N Robinobiose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 OVVGHDNPYGTYIT-VHBGUFLRSA-N 0.000 description 1
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 150000002276 gentiobiuloses Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- PZDOWFGHCNHPQD-OQPGPFOOSA-N kojibiose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-OQPGPFOOSA-N 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- QIGJYVCQYDKYDW-LCOYTZNXSA-N laminarabiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-LCOYTZNXSA-N 0.000 description 1
- JCQLYHFGKNRPGE-HFZVAGMNSA-N maltulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-HFZVAGMNSA-N 0.000 description 1
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 description 1
- OVVGHDNPYGTYIT-BNXXONSGSA-N rutinose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 OVVGHDNPYGTYIT-BNXXONSGSA-N 0.000 description 1
- 150000003308 rutinuloses Chemical class 0.000 description 1
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556124P | 2011-11-04 | 2011-11-04 | |
| US61/556,124 | 2011-11-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540573A Division JP6133883B2 (ja) | 2011-11-04 | 2012-11-02 | 薬物送達用の脂質ナノ粒子の生成方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017165748A JP2017165748A (ja) | 2017-09-21 |
| JP2017165748A5 true JP2017165748A5 (https=) | 2017-12-28 |
| JP6442551B2 JP6442551B2 (ja) | 2018-12-19 |
Family
ID=47178988
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540573A Active JP6133883B2 (ja) | 2011-11-04 | 2012-11-02 | 薬物送達用の脂質ナノ粒子の生成方法 |
| JP2014540571A Active JP6149041B2 (ja) | 2011-11-04 | 2012-11-02 | 脂質−核酸粒子を無菌的に生成するための単回使用システム |
| JP2017083327A Active JP6442551B2 (ja) | 2011-11-04 | 2017-04-20 | 薬物送達用の脂質ナノ粒子の生成方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540573A Active JP6133883B2 (ja) | 2011-11-04 | 2012-11-02 | 薬物送達用の脂質ナノ粒子の生成方法 |
| JP2014540571A Active JP6149041B2 (ja) | 2011-11-04 | 2012-11-02 | 脂質−核酸粒子を無菌的に生成するための単回使用システム |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8956572B2 (https=) |
| EP (4) | EP2773326B1 (https=) |
| JP (3) | JP6133883B2 (https=) |
| KR (2) | KR102046968B1 (https=) |
| CN (2) | CN103906503B (https=) |
| AU (2) | AU2012356239B2 (https=) |
| CA (2) | CA2853685C (https=) |
| CY (1) | CY1121495T1 (https=) |
| DK (1) | DK2773326T3 (https=) |
| ES (1) | ES2721325T3 (https=) |
| HR (1) | HRP20190481T1 (https=) |
| HU (1) | HUE043809T2 (https=) |
| LT (1) | LT2773326T (https=) |
| PL (1) | PL2773326T3 (https=) |
| PT (1) | PT2773326T (https=) |
| RS (1) | RS58562B1 (https=) |
| RU (2) | RU2642640C2 (https=) |
| SI (1) | SI2773326T1 (https=) |
| SM (1) | SMT201900197T1 (https=) |
| TR (1) | TR201904389T4 (https=) |
| TW (3) | TWI618548B (https=) |
| WO (2) | WO2013093648A2 (https=) |
Families Citing this family (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9320297B2 (en) | 2012-03-22 | 2016-04-26 | Lemniscate Innovations Llc | Spherification/reverse spherification automated and integrated system and method |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| SI2858974T1 (sl) | 2012-06-08 | 2019-01-31 | Nitto Denko Corporation | Lipidi za formulacije za dostavo terapevtskega sredstva |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| EP3845248A1 (en) | 2013-02-05 | 2021-07-07 | 1Globe Health Institute LLC | Biodegradable and clinically-compatible nanoparticles as drug delivery carriers |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| SMT202100691T1 (it) * | 2013-07-11 | 2022-01-10 | Modernatx Inc | Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10195291B2 (en) | 2013-09-24 | 2019-02-05 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for the manufacture of lipid nanoparticles |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| CN103599549A (zh) * | 2013-11-22 | 2014-02-26 | 大连民族学院 | 一种siRNA/抗癌药物联合转运复合载体及其制备方法和应用 |
| US20170143848A1 (en) * | 2014-03-24 | 2017-05-25 | Shire Human Genetic Therapies, Inc. | Mrna therapy for the treatment of ocular diseases |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| BR112016030852A2 (pt) * | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| EP3169309B1 (en) * | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| CA2971830A1 (en) * | 2014-12-29 | 2016-07-07 | Bonac Corporation | Composition containing nucleic acid molecule stably |
| JP6764870B2 (ja) * | 2015-02-24 | 2020-10-07 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 連続フローマイクロ流体システム |
| CA2983804C (en) * | 2015-04-28 | 2021-08-17 | The University Of British Columbia | Disposable microfluidic cartridge |
| PL4108769T3 (pl) | 2015-05-29 | 2024-02-05 | CureVac Manufacturing GmbH | Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym |
| SMT202100196T1 (it) | 2015-07-22 | 2021-05-07 | Nitto Denko Corp | Composizioni e metodi per forme liofile di nanoparticelle |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| US9938572B1 (en) * | 2015-09-08 | 2018-04-10 | Raindance Technologies, Inc. | System and method for forming an emulsion |
| PL3350333T3 (pl) | 2015-09-17 | 2022-03-07 | Modernatx, Inc. | Polinukleotydy zawierające region stabilizujący ogon |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| RS63135B1 (sr) | 2015-12-23 | 2022-05-31 | Modernatx Inc | Postupci upotrebe polinukleotida koji kodiraju ox40 ligand |
| AU2016385135B2 (en) | 2016-01-06 | 2022-02-17 | The University Of British Columbia | Bifurcating mixers and methods of their use and manufacture |
| US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| AU2017230823A1 (en) | 2016-03-10 | 2018-09-27 | Lonza Ltd | Customizable facility |
| US10689873B2 (en) | 2016-03-10 | 2020-06-23 | Lonza Ltd | Customizable facility |
| US20200315967A1 (en) * | 2016-06-24 | 2020-10-08 | Modernatx, Inc. | Lipid nanoparticles |
| CN109563511A (zh) * | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
| WO2018026577A1 (en) * | 2016-08-02 | 2018-02-08 | Lonza Ltd | Customizable facility |
| WO2018035388A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| CN110312799A (zh) | 2016-08-17 | 2019-10-08 | 博德研究所 | 新型crispr酶和系统 |
| IL264842B (en) * | 2016-08-18 | 2022-08-01 | Troy Bremer | Delivery of urea to cells of the macula and retina using liposome constructs |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| EP3315125A1 (en) * | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Lipid nanoparticle formulation |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| SMT202300097T1 (it) | 2017-03-15 | 2023-05-12 | Modernatx Inc | Composto e composizioni per il rilascio intracellulare di agenti terapeutici |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| US12350368B2 (en) | 2017-04-14 | 2025-07-08 | The Broad Institute, Inc. | Delivery of large payloads |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| CN111093623A (zh) * | 2017-07-10 | 2020-05-01 | 免疫疫苗技术公司 | 药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途 |
| EP3662913A4 (en) | 2017-08-04 | 2021-06-30 | Kyowa Kirin Co., Ltd. | Nucleic-acid-containing lipid nanoparticles |
| JP2019043216A (ja) | 2017-08-30 | 2019-03-22 | いすゞ自動車株式会社 | ステアリング装置 |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| TW201927288A (zh) | 2017-10-20 | 2019-07-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | 適用於治療之微脂體ｒｎａ配製物的製備及儲存 |
| US12227742B2 (en) | 2017-10-23 | 2025-02-18 | The Broad Institute, Inc. | Nucleic acid modifiers |
| US11638695B2 (en) | 2017-11-01 | 2023-05-02 | Osaka University | Development of method and apparatus for producing lipid particles having desired particle diameter |
| CN111565706A (zh) * | 2017-11-09 | 2020-08-21 | 免疫疫苗技术公司 | 药物组合物、包括脂质囊泡颗粒尺寸设定的制备方法及其用途 |
| EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH |
| US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
| WO2019204451A1 (en) * | 2018-04-17 | 2019-10-24 | Carnegie Mellon University | Enhanced lipid nanoparticle drug delivery using a negatively charged polymer |
| KR20210091120A (ko) * | 2018-08-29 | 2021-07-21 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정 |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CN113271926A (zh) * | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| IL281615B2 (en) * | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| JP7543259B2 (ja) | 2018-10-18 | 2024-09-02 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| CA3112837A1 (en) * | 2018-10-19 | 2020-04-23 | Translate Bio, Inc. | Pumpless encapsulation of messenger rna |
| JP7635131B2 (ja) * | 2019-01-31 | 2025-02-25 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の調製方法 |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| US12534714B2 (en) | 2019-03-18 | 2026-01-27 | The Broad Institute, Inc. | Type VII CRISPR proteins and systems |
| EP3942050A4 (en) * | 2019-03-19 | 2023-02-22 | Arcturus Therapeutics, Inc. | PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES |
| US20220241203A1 (en) | 2019-05-07 | 2022-08-04 | Universidade Do Minho | Method for production of liposomes |
| WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
| US20230097090A1 (en) | 2019-08-14 | 2023-03-30 | Acuitas Therapeutics, Inc. | Improved lipid nanoparticles for delivery of nucleic acids |
| JP7700101B2 (ja) | 2019-09-06 | 2025-06-30 | ジェネレーション バイオ カンパニー | 閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 |
| JP7271374B2 (ja) * | 2019-09-10 | 2023-05-11 | 株式会社東芝 | 分析方法、分析基体、分析キット及び分析装置。 |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| BR112022004936A2 (pt) | 2019-09-19 | 2022-06-14 | Modernatx Inc | Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| AU2020385378A1 (en) | 2019-11-22 | 2022-04-07 | Generation Bio Co. | Ionizable lipids and nanoparticle compositions thereof |
| KR102409145B1 (ko) | 2020-03-23 | 2022-06-15 | 프레스티지바이오로직스 주식회사 | 항체 의약품 제조 공정을 위한 버퍼 조제 및 이송 시스템 |
| CN111467321A (zh) * | 2020-03-26 | 2020-07-31 | 深圳市新合生物医疗科技有限公司 | 一种mRNA核酸类药物胞内递送系统、制备方法和应用 |
| IL296763B2 (en) | 2020-03-27 | 2026-04-01 | Generation Bio Co | New lipids and their nanoparticle compositions |
| IL299271A (en) | 2020-06-24 | 2023-02-01 | Bristol Myers Squibb Co | A process for the synthesis of cationic lipids |
| WO2022016070A1 (en) | 2020-07-16 | 2022-01-20 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| US12178921B2 (en) * | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| WO2022056413A1 (en) | 2020-09-13 | 2022-03-17 | Arcturus Therapeutics, Inc. | Lipid nanoparticles encapsulation of large rna |
| JP2023546175A (ja) | 2020-10-14 | 2023-11-01 | ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド | 脂質ナノ粒子製造の方法及びそれに由来する組成物 |
| CN112843019A (zh) * | 2021-01-27 | 2021-05-28 | 江苏普瑞康生物医药科技有限公司 | 一种核酸脂质纳米粒组合物，包含其的药物制剂，及其制备方法和应用 |
| EP4294450B1 (en) * | 2021-02-16 | 2026-02-04 | The Johns Hopkins University | Methods for preparation of plasmid dna/lipid particles with defined size for in vitro and in vivo transfection |
| WO2022175366A1 (en) | 2021-02-17 | 2022-08-25 | Secoya Technologies | Method for producing lipid nanoparticles and lipid nanoparticles resulting therefrom |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022225368A1 (ko) * | 2021-04-22 | 2022-10-27 | (주)인벤티지랩 | 지질 나노입자의 제조 방법 및 이의 제조 장치 |
| KR20240008872A (ko) * | 2021-05-06 | 2024-01-19 | 아크투루스 쎄라퓨틱스, 인크. | Rna 전달을 위한 이온화 가능한 양이온성 지질 |
| WO2022266032A1 (en) | 2021-06-14 | 2022-12-22 | Generation Bio Co. | Cationic lipids and compositions thereof |
| WO2023057596A1 (en) * | 2021-10-06 | 2023-04-13 | Leon-Nanodrugs Gmbh | Method for preparing lipid nanoparticles |
| EP4430024A1 (en) | 2021-11-08 | 2024-09-18 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
| CN116549626A (zh) * | 2022-01-27 | 2023-08-08 | 深圳瑞吉生物科技有限公司 | 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用 |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| CN119562762A (zh) | 2022-04-04 | 2025-03-04 | 加利福尼亚大学董事会 | 遗传互补组合物和方法 |
| KR102475540B1 (ko) * | 2022-04-26 | 2022-12-08 | 주식회사 무진메디 | 약물이 담지된 지질 나노입자 제조 방법 및 제조 장치 |
| EP4536197A1 (en) | 2022-06-07 | 2025-04-16 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| TW202425959A (zh) | 2022-11-08 | 2024-07-01 | 美商歐納醫療公司 | 遞送多核苷酸的脂質及奈米顆粒組合物 |
| CN120390656A (zh) | 2022-11-08 | 2025-07-29 | 欧纳医疗公司 | 环状rna组合物 |
| JP2025540076A (ja) | 2022-12-01 | 2025-12-11 | ジェネレーション バイオ カンパニー | 核酸、イオン化可能な脂質、ステロール、脂質アンカーポリマー、及びヘルパー脂質を含む脂質ナノ粒子、それらの使用 |
| WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| KR20250131271A (ko) | 2022-12-01 | 2025-09-02 | 제너레이션 바이오 컴퍼니 | 신규한 폴리글리세롤-접합된 지질 및 이를 포함하는 지질 나노입자 조성물 |
| KR20250114116A (ko) | 2022-12-01 | 2025-07-28 | 제너레이션 바이오 컴퍼니 | 세포 표적화를 위한 스텔스 지질 나노입자 조성물 |
| AU2023398825A1 (en) | 2022-12-15 | 2025-06-26 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2024136254A1 (ko) * | 2022-12-20 | 2024-06-27 | (주)인벤티지랩 | 저농도 이온화 지질을 포함하는 지질나노입자 및 이의 제조 방법 |
| WO2024205657A2 (en) | 2023-03-29 | 2024-10-03 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| WO2024233308A2 (en) | 2023-05-05 | 2024-11-14 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2025052180A2 (en) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2025051994A1 (en) | 2023-09-07 | 2025-03-13 | Coave Therapeutics | Ionizable lipid nanoparticles |
| WO2025072383A1 (en) | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025101501A1 (en) | 2023-11-07 | 2025-05-15 | Orna Therapeutics, Inc. | Circular rna compositions |
| WO2025114520A1 (en) | 2023-12-01 | 2025-06-05 | Coave Therapeutics | Ionizable lipid nanoparticles |
| EP4570361A1 (en) * | 2023-12-11 | 2025-06-18 | Sartorius Stedim Biotech GmbH | Device assembly and method for a production-scale tangential flow filtration |
| WO2025129158A1 (en) | 2023-12-15 | 2025-06-19 | The Broad Institute, Inc. | Engineered arc delivery vesicles and uses thereof |
| WO2025166238A1 (en) | 2024-01-31 | 2025-08-07 | Orna Therapeutics, Inc. | Fast-shedding polyethylene glycol lipids |
| WO2025250808A1 (en) | 2024-05-29 | 2025-12-04 | The Brigham And Women’S Hospital, Inc. | Anti-crispr delivery compositions and methods |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| DE102024002527A1 (de) * | 2024-08-02 | 2026-02-05 | Rommelag Engineering Gmbh | Vorrichtung |
| WO2026064512A1 (en) | 2024-09-18 | 2026-03-26 | Generation Bio Co. | Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988001864A1 (en) * | 1986-09-18 | 1988-03-24 | Liposome Technology, Inc. | High-concentration liposome processing method |
| US4781871A (en) * | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
| US4895452A (en) | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
| WO1995001164A1 (en) * | 1993-06-30 | 1995-01-12 | Genentech, Inc. | Method for preparing liposomes |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| ATE285477T1 (de) | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
| CA2289702C (en) * | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6855296B1 (en) | 1998-11-13 | 2005-02-15 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
| WO2000029103A1 (en) | 1998-11-13 | 2000-05-25 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
| US7094423B1 (en) | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
| CA2378430A1 (en) * | 1999-07-15 | 2001-01-25 | Inex Pharmaceuticals Corp. | Methods and apparatus for preparation of lipid vesicles |
| EP1203614A1 (de) | 2000-11-03 | 2002-05-08 | Polymun Scientific Immunbiologische Forschung GmbH | Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln |
| EP1306127B2 (en) | 2001-10-26 | 2011-09-07 | OctoPlus PolyActive Sciences B.V. | Method for the preparation of purified microparticles |
| US7223887B2 (en) | 2001-12-18 | 2007-05-29 | The University Of British Columbia | Multivalent cationic lipids and methods of using same in the production of lipid particles |
| EP1471885A4 (en) | 2002-01-09 | 2009-04-22 | Transave Inc | EFFECTIVE LIPOSOM ASSORTMENT |
| US6712963B2 (en) | 2002-06-14 | 2004-03-30 | Scilog, Llc | Single-use manifold for automated, aseptic transfer of solutions in bioprocessing applications |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| FR2856940B1 (fr) * | 2003-07-04 | 2007-02-09 | Stedim Sa | Systeme clos a usage unique de melange, de stockage et d'homogeneisation de liquides en conditions propres ou steriles |
| WO2005090403A2 (en) * | 2004-03-12 | 2005-09-29 | Biovest International, Inc. | Method and apparatus for antibody purification |
| MXPA06014099A (es) | 2004-06-04 | 2007-05-09 | Xcellerex Inc | Sistemas biorreactores desechables y metodos. |
| US7410587B2 (en) | 2004-08-03 | 2008-08-12 | Scilog, Inc. | Liquid handling for filtration and preparative chromatography |
| US7404969B2 (en) * | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| US9005654B2 (en) | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| US8101741B2 (en) * | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| CA2649025A1 (en) | 2006-04-11 | 2007-10-18 | Wingturf Co., Ltd. | Production method of liposome dispersion and production equipment thereof |
| EP1920765A1 (en) | 2006-11-07 | 2008-05-14 | Medigene AG | Liposome preparation by single-pass process |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| JP5322476B2 (ja) | 2008-03-31 | 2013-10-23 | テルモ株式会社 | リポソームの製造装置およびリポソームの製造方法 |
| US8231787B2 (en) | 2008-05-06 | 2012-07-31 | Spf Innovations, Llc | Tangential flow filtration system |
| US20110224447A1 (en) * | 2008-08-18 | 2011-09-15 | Bowman Keith A | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids |
| CN102231979B (zh) | 2008-10-16 | 2014-10-29 | 玛瑞纳生物技术有限公司 | 基因沉默治疗剂的脂质体有效递送方法和组合物 |
| TW201021853A (en) * | 2008-11-17 | 2010-06-16 | Enzon Pharmaceuticals Inc | Releasable cationic lipids for nucleic acids delivery systems |
| WO2010080724A1 (en) * | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| US8911816B2 (en) * | 2009-01-20 | 2014-12-16 | Johan Claes Wilhelm Axelsson | Coating composition and use thereof |
| FR2943560B1 (fr) * | 2009-03-24 | 2011-05-27 | Jean Pascal Zambaux | Bioreacteur jetable et systeme d'agitation a usage unique |
| CA2816925C (en) * | 2009-11-04 | 2023-01-10 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
| HUE042177T2 (hu) * | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| US20130116419A1 (en) * | 2010-01-22 | 2013-05-09 | Daniel Zewge | Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry |
| EP2558074B1 (en) | 2010-04-08 | 2018-06-06 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
| CN107043334B (zh) * | 2011-06-08 | 2020-06-16 | 日东电工株式会社 | 用于定向药物输送和增强siRNA活性的化合物 |
-
2012
- 2012-11-02 CA CA2853685A patent/CA2853685C/en active Active
- 2012-11-02 AU AU2012356239A patent/AU2012356239B2/en active Active
- 2012-11-02 WO PCT/IB2012/003109 patent/WO2013093648A2/en not_active Ceased
- 2012-11-02 DK DK12829180.4T patent/DK2773326T3/en active
- 2012-11-02 KR KR1020147014822A patent/KR102046968B1/ko active Active
- 2012-11-02 EP EP12829180.4A patent/EP2773326B1/en active Active
- 2012-11-02 PT PT12829180T patent/PT2773326T/pt unknown
- 2012-11-02 PL PL12829180T patent/PL2773326T3/pl unknown
- 2012-11-02 AU AU2012330819A patent/AU2012330819B2/en active Active
- 2012-11-02 RU RU2014122433A patent/RU2642640C2/ru active
- 2012-11-02 LT LTEP12829180.4T patent/LT2773326T/lt unknown
- 2012-11-02 ES ES12829180T patent/ES2721325T3/es active Active
- 2012-11-02 RU RU2014122432A patent/RU2647476C2/ru active
- 2012-11-02 WO PCT/IB2012/002916 patent/WO2013064911A2/en not_active Ceased
- 2012-11-02 SI SI201231557T patent/SI2773326T1/sl unknown
- 2012-11-02 JP JP2014540573A patent/JP6133883B2/ja active Active
- 2012-11-02 JP JP2014540571A patent/JP6149041B2/ja active Active
- 2012-11-02 HR HRP20190481TT patent/HRP20190481T1/hr unknown
- 2012-11-02 HU HUE12829180A patent/HUE043809T2/hu unknown
- 2012-11-02 RS RS20190426A patent/RS58562B1/sr unknown
- 2012-11-02 CA CA2853689A patent/CA2853689C/en active Active
- 2012-11-02 CN CN201280054023.XA patent/CN103906503B/zh active Active
- 2012-11-02 TR TR2019/04389T patent/TR201904389T4/tr unknown
- 2012-11-02 KR KR1020147014826A patent/KR102056702B1/ko active Active
- 2012-11-02 EP EP18209774.1A patent/EP3485875A1/en not_active Ceased
- 2012-11-02 CN CN201280054027.8A patent/CN103906504B/zh active Active
- 2012-11-02 EP EP12848760.0A patent/EP2773328A2/en not_active Withdrawn
- 2012-11-02 SM SM20190197T patent/SMT201900197T1/it unknown
- 2012-11-02 EP EP19205352.8A patent/EP3673898A1/en not_active Ceased
- 2012-11-05 TW TW101141082A patent/TWI618548B/zh active
- 2012-11-05 TW TW101141084A patent/TWI615156B/zh active
- 2012-11-05 TW TW106116691A patent/TWI626952B/zh not_active IP Right Cessation
- 2012-11-05 US US13/669,217 patent/US8956572B2/en active Active
-
2017
- 2017-04-20 JP JP2017083327A patent/JP6442551B2/ja active Active
-
2019
- 2019-03-28 CY CY20191100358T patent/CY1121495T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017165748A5 (https=) | ||
| RU2014122432A (ru) | Способ получения липидных наночастиц для доставки лекарственного средства | |
| Charoenviriyakul et al. | Preservation of exosomes at room temperature using lyophilization | |
| JP5851550B2 (ja) | 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用 | |
| WO2023018773A1 (en) | Lipid nanoparticle formulations and methods of synthesis thereof | |
| Jiang et al. | The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization | |
| EP0035429B1 (fr) | Complexe vaccinal contenant un antigène spécifique et vaccin le contenant | |
| CN104013955A (zh) | 一种不含表面活性剂的水包油乳液及其用途 | |
| JP2014514275A5 (https=) | ||
| TW202237148A (zh) | 包含rna之lnp組合物以及製備、儲存及使用彼之方法 | |
| KR20110118779A (ko) | 국소 투여용으로 적당한 이미다조퀴놀린（아민）및 이의 유도체를 포함하는 약학 조성물 | |
| JP2015501791A (ja) | 新規な遺伝子伝達用組成物 | |
| RU2019103434A (ru) | Состав для введения рнк | |
| US20260062716A1 (en) | Lipid nanoparticle (lnp) composition or formulation for nucleic acid therapeutics | |
| US20250195642A1 (en) | Nucleic acid stabilizing solution for vaccines, therapy, diagnostics, storage, and transport | |
| CN118265522A (zh) | 适用于治疗的基于脂质的rna制剂 | |
| CN119968210A (zh) | 用于预防或治疗结核病的rna | |
| Wang et al. | Advances of nanotechnology toward vaccine development against animal infectious diseases | |
| CN113679831B (zh) | 一种注射用水包油型乳剂黏膜疫苗及其制备方法和应用 | |
| Gu et al. | Poria cocos polysaccharide-loaded Alum Pickering emulsion as vaccine adjuvant to enhance immune responses | |
| JPWO2022036170A5 (https=) | ||
| Porte et al. | A molecular view of lipid nanoparticles: insights into their morphology and structural plasticity | |
| JP2019534897A5 (https=) | ||
| JP2026015426A (ja) | ワクチンアジュバントとしてのポリマーナノ粒子 | |
| CN103007294A (zh) | 一种多价免疫刺激纳米制剂及其制备方法和应用 |